Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
The inflammatory bowel diseases (IBD), which consist of Crohn’s disease and ulcerative colitis, are chronic, incurable immunemediated inflammatory disorders of the intestine. As IBD incidence continues to increase globally and its mortality is low, prevalent cases of IBD are rapidly increasing, ther...
Main Authors: | Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of Intestinal Diseases
2020-01-01
|
Series: | Intestinal Research |
Subjects: | |
Online Access: | http://www.irjournal.org/upload/pdf/ir-2019-09147.pdf |
Similar Items
-
Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01) -
Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01) -
Are We Ready for Biosimilars in Gastroenterology?
by: Muhammad Ilham Abdul Hafidz, et al.
Published: (2017-12-01) -
Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD
by: Amanda M Johnson, et al.
Published: (2021-01-01) -
INFLAMMATORY BOWEL DISEASE
by: I Gusti Ayu Mahaprani Danastri, et al.
Published: (2013-02-01)